Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OAV101 in pediatric type 2 spinal muscular atrophy
CTR20220992Phase 3Completed
- Sponsor
- Novartis
- Start
- Apr 2022
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
A Phase 3 trial of onasemnogene abeparvovec in spinal muscular atrophy (SMA), sponsored by Novartis. Started Apr 2022; status: completed.
02
Drugs
onasemnogene abeparvovec
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on CTR20220992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220992.